(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 March 2014 (27.03.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/045226 A1

(51) International Patent Classification:
A61K 39/08 (2006.01) *C07K 16/12* (2006.01)
A61K 39/40 (2006.01) *C12N 15/31* (2006.01)
C07K 14/33 (2006.01) *A61P 31/04* (2006.01)

(21) International Application Number:
PCT/IB2013/058673

(22) International Filing Date:
19 September 2013 (19.09.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1216748.2 19 September 2012 (19.09.2012) GB
1216749.0 19 September 2012 (19.09.2012) GB

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors: **GALEOTTI, Cesira**; Novartis Vaccines & Diagnostics, S.r.l., Via Fiorentina 1, I-53100 Siena (IT). **LEUZZI, Rosanna**; Novartis Vaccines & Diagnostics, S.r.l., Via Fiorentina 1, I-53100 Siena (IT). **PIZZA, Mariagrazia**; Novartis Vaccines & Diagnostics, S.r.l., Via Fiorentina 1, I-53100 Siena (IT). **SCARSELLI, Maria**; Novartis Vaccines & Diagnostics, S.r.l., Via Fiorentina 1, I-53100 Siena (IT). **UNNIKRISHNAN, Meera**; Novartis Vaccines & Diagnostics, S.r.l., Via Fiorentina 1, I-53100 Siena (IT). **MARTINELLI, Manuele**; Novartis Vaccines & Diagnostics, S.r.l., Via Fiorentina 1, I-53100 Siena (IT).

(74) Agents: **BULLETT, Rachel Margaret** et al.; Carpmaels & Ransford LLP, One Southampton Row, London Greater London WC1B 5HA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: CLOSTRIDIUM DIFFICILE POLYPEPTIDES AS VACCINE

(57) Abstract: The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating a *C. difficile* infection in a mammal.




Fig. 24

WO 2014/045226 A1

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*